PET Scanners Market Outlook:
PET Scanners Market size was valued at USD 2.5 billion in 2025 and is projected to reach USD 3.6 billion by the end of 2035, rising at a CAGR of 3.9% during the forecast period, i.e., 2026-2035. In 2026, the industry size of PET scanners is assessed at USD 2.6 billion.
The global PET scanners market is expanding due to the rising burden of chronic illness, mainly among patients with neurological and cancer disorders. According to the WHO February 2024 report, 1 in 5 people develop cancer, with nearly 1 in 9 men and 1 in 12 women dying from cancer, which is a vital driver for advanced imaging systems, including PET scanners. Further, Alzheimer's disease is also an important diagnosis requiring PET scanners. As per the NLM report published in May 2024, above 6.9 million patients in the U.S. are affected by Alzheimer's disease in 2024, which is expected to double in the upcoming years. This rise in patient volume is impacting the procurement rates for PET scanners in major diagnostic centers and healthcare systems.
On the supply chain side, the manufacturing of PET scanners is driven by both radiopharmaceutical tracer logistics and medical device components. Nuclear materials used in PET tracers are subject to regulatory control, according to the U.S. Energy Information Administration and the FDA, and delays in isotope manufacturing, such as molybdenum-99, in 2023 affected diagnostic scheduling. As per the FDA report in 2023, nearly 21 PET drugs are approved by the FDA in the U.S., and more than 50 new PET drugs are in development as companion imaging agents for theranostic agents. These values highlight the growth and demand for the market.
